Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience
European Journal of Haematology · 2026-07 · 117 (1) · 144-153
DOI: 10.1111/ejh.70183 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 06.04.2026. Verfasst von Francesca Bonello und 7 weiteren Autor:innen. Beteiligte Einrichtung: Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Immunoconjugates, Antineoplastic Agents. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health.
Abstract (Originalsprache)
Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is a second‐in‐class agent approved for the treatment of patients with R/R DLBCL after ≥ 2 lines of systemic therapy. Because many patients with R/R DLBCL are ineligible for intensive therapies due to advanced age and comorbidities, the availability of any new agent is particularly important. We present an overview of the clinical evidence for loncastuximab tesirine and offer practical guidance on its use in R/R DLBCL. Additionally, three clinical cases are described to illustrate its efficacy in transformed DLBCL, the management of treatment and safety when used as a bridge to allogeneic stem cell transplantation, and its role in the sequencing of therapies for R/R DLBCL. Findings from our Italian experience may be informative on the clinical application of loncastuximab tesirine in other countries where it is approved and available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
- Hematology Division, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
- School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
- Division of Hematology, AO Santa Croce e Carle, Cuneo, Italy.
- Laboratory of Blood Tumor Immunology, Molecular Biotechnology Center "Guido Tarone", University of Torino, Torino, Italy.
- Unit of Onco Hematology, Department of Oncology, Azienda USL Toscana Centro, Prato, Italy.
ORCID-Profile: Umberto Vitolo
Förderung
- Ministry of Health
Zitieren
APA
Bonello, F., Aroldi, A., Castellino, A., Mannelli, L., Boccellato, E., Rosati, S., Verga, L., & Vitolo, U. (2026). Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience. European Journal of Haematology, 117(1), 144-153. https://doi.org/10.1111/ejh.70183
Vancouver
Bonello F, Aroldi A, Castellino A, Mannelli L, Boccellato E, Rosati S, et al. Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience. European Journal of Haematology. 2026;117(1):144-153. doi:10.1111/ejh.70183
BibTeX
@article{Bonello2026,
author = {Bonello, Francesca and Aroldi, Andrea and Castellino, Alessia and Mannelli, Lara and Boccellato, Elia and Rosati, Serena and Verga, Luisa and Vitolo, Umberto},
title = {Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {1},
pages = {144--153},
doi = {10.1111/ejh.70183}
}
EUVIMED